Participant flow

A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia · Source last updated 2016-06-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   All participants enrolled. 5-Azacitidine: Administered on Days 1-7 of each Cycle. Subcutaneous administration: To provide a homogeneous suspension, the contents of the syringe must be re-suspended by inverting the syringe 2-3 times and vigorously rolling the syringe between the palms for 30 seconds immediately prior to administration. The 5-azacitidine suspension is administered subcutaneously. Intravenous Administration: 5-Azacitidine solution is administered intravenously. Administer the total dose over a period of 10-40 minutes.

   id

   FG000

   title

   Arm 1 - 5-Azacitidine

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         11

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         11

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice